One representative case is the assessment of the genistein-cisplatin treatment of non-small cell lung cancer (NSCLC) in xenografted mice models, in order to prove the sensitization of drug-resistant cancer cells via enhanced activity of caspase-3, 8, 10 and suppression of PI3K/AKT activity [262]. This evidence concerns the gene CASP3 and non-small cell lung carcinoma.